GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDC

Phase 2/3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV-1-infection

Conditions

HIV-1-infection

Trial Timeline

Oct 21, 2024 → Aug 1, 2030

NCT ID

NCT06613685

About GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDC

GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDC is a phase 2/3 stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is active. This product is registered under clinical trial identifier NCT06613685. Target conditions include HIV-1-infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06613685	Phase 2/3	Active	Oct 21, 2024	Aug 1, 2030	HIV-1-infection

Competing Products

20 competing products in HIV-1-infection

See all competitors

Product	Company	Stage	Hype Score
CVC 150 mg + CVC 300 mg	AbbVie	Phase 2	52
18F-Raltegravir	Merck	Phase 1	33
ISL/LEN + Antiretroviral Combinations	Merck	Phase 3	77
Delstrigo + KOCITAF	Merck	Phase 3	77
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LEN	Merck	Phase 3	77
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla Placebo	Gilead Sciences	Approved	84
GS-3242 + BVY + Standard of Care	Gilead Sciences	Phase 1	32
B/F/TAF	Gilead Sciences	Approved	84
Genvoya + Epclusa + Biktarvy	Gilead Sciences	Approved	84
Dapivirine + Truvada	Gilead Sciences	Phase 2	51
Bictegravir/emtricitabine/tenofovir alafenamide	Gilead Sciences	Pre-clinical	22
GS-9131 + BIC + TAF + ARV regimen + DRV + RTV	Gilead Sciences	Phase 2	51
Bavtavirine + B/F/TAF + Standard of Care (Substudy 01) + GS-1720 + Standard of Care (Substudy 02) + GS-6212 + Standard of Care (Substudy 03)	Gilead Sciences	Phase 1	32
Truvada	Gilead Sciences	Phase 2	51
B/F/TAF	Gilead Sciences	Phase 1	32
Switch to B/F/TAF + Continue current regimen	Gilead Sciences	Approved	84
B/F/TAF + F/TAF + DTG + DTG Placebo + F/TAF Placebo + B/F/TAF Placebo	Gilead Sciences	Phase 3	76
GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDC	Gilead Sciences	Phase 2/3	64
Vesatolimod + VRC07523LS + CAP256V2LS	Gilead Sciences	Phase 2	51
F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)	Gilead Sciences	Approved	84

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved